OncoCyte (OCX) Stock Forecast, Price Target & Predictions
OCX Stock Forecast
OncoCyte stock forecast is as follows: an average price target of $8.08 (represents a 162.34% upside from OCX’s last price of $3.08) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
OCX Price Target
The average price target for OncoCyte (OCX) is $8.08 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $4.25. This represents a potential 162.34% upside from OCX's last price of $3.08.
OCX Analyst Ratings
According to 4 Wall Street analysts, OncoCyte's rating consensus is 'Buy'. The analyst rating breakdown for OCX stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
OncoCyte Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 24, 2024 | Mike Matson | Needham | $4.25 | $2.38 | 78.57% | 37.99% |
| Dec 01, 2022 | - | Lake Street | $10.00 | $9.44 | 5.95% | 224.68% |
| Nov 18, 2022 | - | Piper Sandler | $10.00 | $8.52 | 17.32% | 224.68% |
| Aug 17, 2022 | David Westenberg | Piper Sandler | $30.00 | $17.48 | 71.61% | 874.03% |
| Aug 11, 2022 | - | Lake Street | $60.00 | $19.27 | 211.30% | 1848.05% |
| Aug 11, 2022 | - | Needham | $42.00 | $19.02 | 120.84% | 1263.64% |
| May 15, 2022 | David Westenberg | Piper Sandler | $28.00 | $22.60 | 23.89% | 809.09% |
The latest OncoCyte stock forecast, released on Apr 24, 2024 by Mike Matson from Needham, set a price target of $4.25, which represents a 78.57% increase from the stock price at the time of the forecast ($2.38), and a 37.99% increase from OCX last price ($3.08).
OncoCyte Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $4.25 |
| Last Closing Price | $3.08 | $3.08 | $3.08 |
| Upside/Downside | -100.00% | -100.00% | 37.99% |
In the current month, the average price target of OncoCyte stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to OncoCyte's last price of $3.08. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 16, 2024 | Stephens | Buy | Buy | Hold |
| Apr 24, 2024 | Needham | Buy | Buy | Hold |
| Nov 18, 2022 | Piper Sandler | Overweight | Neutral | Downgrade |
| Nov 14, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Nov 11, 2022 | Needham | Buy | Buy | Hold |
| Aug 17, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 11, 2022 | Lake Street | Buy | Buy | Hold |
| Aug 11, 2022 | Needham | Buy | Buy | Hold |
| May 15, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| May 12, 2022 | Needham | Buy | Buy | Hold |
OncoCyte's last stock rating was published by Stephens on May 16, 2024. The company gave OCX a "Buy" rating, the same as its previous rate.
OncoCyte Financial Forecast
OncoCyte Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Jun 18 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $429.00K | - | $297.00K | $-3.55M | $1.02M | $2.07M | $1.42M | $3.59M | $984.00K | $2.03M | $1.12M | $503.00K | $555.00K | $143.00K | $16.00K | - | - |
| Avg Forecast | $2.90M | $2.47M | $2.07M | $1.80M | $775.65K | $343.55K | $245.45K | $207.90K | $120.30K | $116.85K | $318.55K | $350.00K | $225.00K | $312.50K | $362.50K | $346.40K | $1.48M | $2.71M | $2.24M | $3.52M | $1.75M | $1.57M | $838.02K | $807.90K | $366.67K | $47.20K | $102.14K | $13.54K | $42.75K | $55.00K |
| High Forecast | $2.90M | $2.47M | $2.07M | $1.80M | $775.65K | $343.55K | $245.45K | $207.90K | $120.30K | $116.85K | $318.55K | $350.00K | $225.00K | $312.50K | $362.50K | $346.40K | $1.48M | $2.71M | $2.24M | $3.52M | $1.75M | $1.57M | $838.02K | $807.90K | $366.67K | $47.20K | $122.57K | $16.25K | $51.30K | $66.00K |
| Low Forecast | $2.90M | $2.47M | $2.07M | $1.80M | $775.65K | $343.55K | $245.45K | $207.90K | $120.30K | $116.85K | $318.55K | $350.00K | $225.00K | $312.50K | $362.50K | $346.40K | $1.48M | $2.71M | $2.24M | $3.52M | $1.75M | $1.57M | $838.02K | $807.90K | $366.67K | $47.20K | $81.71K | $10.83K | $34.20K | $44.00K |
| # Analysts | - | - | - | - | - | - | - | - | - | 1 | - | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 10 | 10 | 10 | 10 | 10 | 10 | 20 | 9 | 16 | 16 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.37% | - | 0.86% | -2.39% | 0.38% | 0.92% | 0.40% | 2.05% | 0.63% | 2.42% | 1.39% | 1.37% | 11.76% | 1.40% | 1.18% | - | - |
OncoCyte's average Quarter revenue forecast for Dec 23 based on 2 analysts is $225.00K, with a low forecast of $225.00K, and a high forecast of $225.00K. OCX's average Quarter revenue forecast represents a -47.55% decrease compared to the company's last Quarter revenue of $429.00K (Sep 23).
OncoCyte EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Jun 18 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | 1 | - | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 10 | 10 | 10 | 10 | 10 | 10 | 20 | 9 | 16 | 16 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-6.51M | - | $-6.17M | $13.45M | $-13.38M | $-14.64M | $-13.37M | $-34.66M | $-12.55M | $-10.77M | $-10.96M | $-6.19M | $-5.78M | $-8.95M | $-8.58M | $-4.29M | $-3.55M |
| Avg Forecast | $-1.74M | $-1.48M | $-1.24M | $-1.08M | $-465.39K | $-206.13K | $-147.27K | $-124.74K | $-72.18K | $-70.11K | $-191.13K | $-8.57M | $-135.00K | $-187.50K | $-217.50K | $-9.16M | $-890.79K | $-8.72M | $-1.34M | $-9.80M | $-350.67K | $-9.33M | $-6.73M | $-14.80M | $-73.33K | $-9.44K | $-5.85M | $-7.02M | $-2.71M | $-3.40M |
| High Forecast | $-1.74M | $-1.48M | $-1.24M | $-1.08M | $-465.39K | $-206.13K | $-147.27K | $-124.74K | $-72.18K | $-70.11K | $-191.13K | $-6.85M | $-135.00K | $-187.50K | $-217.50K | $-7.33M | $-890.79K | $-6.98M | $-1.34M | $-7.84M | $-350.67K | $-7.46M | $-5.38M | $-11.84M | $-73.33K | $-9.44K | $-4.68M | $-5.61M | $-2.17M | $-2.72M |
| Low Forecast | $-1.74M | $-1.48M | $-1.24M | $-1.08M | $-465.39K | $-206.13K | $-147.27K | $-124.74K | $-72.18K | $-70.11K | $-191.13K | $-10.28M | $-135.00K | $-187.50K | $-217.50K | $-11.00M | $-890.79K | $-10.47M | $-1.34M | $-11.76M | $-350.67K | $-11.19M | $-8.07M | $-17.76M | $-73.33K | $-9.44K | $-7.03M | $-8.42M | $-3.25M | $-4.08M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.74% | - | 0.67% | -15.10% | 1.53% | 10.89% | 1.36% | 98.85% | 1.35% | 1.60% | 0.74% | 84.46% | 612.25% | 1.53% | 1.22% | 1.58% | 1.04% |
1 analysts predict OCX's average Quarter EBITDA for Mar 23 to be $-9.16M, with a high of $-7.33M and a low of $-11.00M. This is -168.13% lower than OncoCyte's previous annual EBITDA (Dec 22) of $13.45M.
OncoCyte Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Jun 18 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | 1 | - | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 10 | 10 | 10 | 10 | 10 | 10 | 20 | 9 | 16 | 16 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-6.69M | - | $3.03M | $-45.34M | $-9.45M | $-8.04M | $-10.69M | $-35.88M | $-13.80M | $-10.49M | $-3.92M | $-6.31M | $-6.78M | $-9.11M | $-7.73M | $-4.50M | $-3.78M |
| Avg Forecast | $-4.66M | $-4.88M | $-5.08M | $-5.23M | $-5.86M | $-5.73M | $-6.18M | $-5.86M | $-5.92M | $-5.86M | $-7.21M | $-9.75M | $-9.01M | $-12.98M | $-16.70M | $-10.42M | $-29.17M | $-9.59M | $-20.07M | $-11.15M | $-18.99M | $-10.25M | $-6.56M | $-5.29M | $-15.96M | $-17.17M | $-6.01M | $-6.33M | $-3.00M | $-3.43M |
| High Forecast | $-4.66M | $-4.88M | $-5.08M | $-5.23M | $-5.86M | $-5.73M | $-6.18M | $-5.86M | $-5.92M | $-5.73M | $-7.21M | $-7.80M | $-9.01M | $-12.98M | $-16.70M | $-8.34M | $-29.17M | $-7.67M | $-20.07M | $-8.92M | $-18.99M | $-8.20M | $-5.25M | $-4.23M | $-15.96M | $-17.17M | $-4.81M | $-5.06M | $-2.40M | $-2.75M |
| Low Forecast | $-4.66M | $-4.88M | $-5.08M | $-5.23M | $-5.86M | $-5.73M | $-6.18M | $-5.86M | $-5.92M | $-6.12M | $-7.21M | $-11.70M | $-9.01M | $-12.98M | $-16.70M | $-12.51M | $-29.17M | $-11.50M | $-20.07M | $-13.38M | $-18.99M | $-12.30M | $-7.87M | $-6.35M | $-15.96M | $-17.17M | $-7.21M | $-7.59M | $-3.60M | $-4.12M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.52% | - | -0.29% | 1.55% | 0.99% | 0.40% | 0.96% | 1.89% | 1.35% | 1.60% | 0.74% | 0.40% | 0.39% | 1.52% | 1.22% | 1.50% | 1.10% |
OncoCyte's average Quarter net income forecast for Jun 23 is $-16.70M, with a range of $-16.70M to $-16.70M. OCX's average Quarter net income forecast represents a -650.57% decrease compared to the company's last Quarter net income of $3.03M (Mar 23).
OncoCyte SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Jun 18 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | 1 | - | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 10 | 10 | 10 | 10 | 10 | 10 | 20 | 9 | 16 | 16 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $3.20M | - | $4.11M | $-4.00M | $9.21M | $9.03M | $8.89M | $7.45M | $8.43M | $10.61M | $7.02M | $5.28M | $6.56M | $5.32M | $6.12M | $1.90M | $2.44M |
| Avg Forecast | $33.57M | $28.59M | $23.96M | $20.81M | $8.97M | $3.97M | $2.84M | $2.40M | $1.39M | $1.35M | $3.68M | $4.05M | $2.60M | $3.61M | $4.19M | $4.00M | $17.16M | $31.28M | $25.91M | $34.89M | $17.36M | $15.58M | $8.30M | $8.00M | $3.63M | $467.32K | $1.01M | $134.04K | $423.26K | $544.54K |
| High Forecast | $33.57M | $28.59M | $23.96M | $20.81M | $8.97M | $3.97M | $2.84M | $2.40M | $1.39M | $1.35M | $3.68M | $4.05M | $2.60M | $3.61M | $4.19M | $4.00M | $17.16M | $31.28M | $25.91M | $34.89M | $17.36M | $15.58M | $8.30M | $8.00M | $3.63M | $467.32K | $1.21M | $160.84K | $507.91K | $653.45K |
| Low Forecast | $33.57M | $28.59M | $23.96M | $20.81M | $8.97M | $3.97M | $2.84M | $2.40M | $1.39M | $1.35M | $3.68M | $4.05M | $2.60M | $3.61M | $4.19M | $4.00M | $17.16M | $31.28M | $25.91M | $34.89M | $17.36M | $15.58M | $8.30M | $8.00M | $3.63M | $467.32K | $809.03K | $107.22K | $338.61K | $435.64K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.89% | - | 1.03% | -0.23% | 0.29% | 0.35% | 0.25% | 0.43% | 0.54% | 1.28% | 0.88% | 1.46% | 14.04% | 5.26% | 45.62% | 4.50% | 4.49% |
OncoCyte's average Quarter SG&A projection for Dec 23 is $2.60M, based on 2 Wall Street analysts, with a range of $2.60M to $2.60M. The forecast indicates a -18.71% fall compared to OCX last annual SG&A of $3.20M (Sep 23).
OncoCyte EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Jun 18 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | 1 | - | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 10 | 10 | 10 | 10 | 10 | 10 | 20 | 9 | 16 | 16 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.81 | - | $0.02 | $-0.41 | $-0.08 | $-0.07 | $-0.12 | $-0.39 | $-0.15 | $-0.12 | $-0.05 | $-0.09 | $-0.10 | $-0.14 | $-0.13 | $-0.12 | $-0.12 |
| Avg Forecast | $-0.36 | $-0.38 | $-0.40 | $-0.41 | $-0.46 | $-0.45 | $-0.48 | $-0.46 | $-0.46 | $-0.46 | $-0.56 | $-0.67 | $-0.70 | $-1.01 | $-1.30 | $-1.80 | $-2.27 | $-2.40 | $-2.43 | $-2.46 | $-2.30 | $-2.01 | $-1.97 | $-2.15 | $-1.93 | $-2.08 | $-2.25 | $-1.76 | $-0.06 | $-0.10 |
| High Forecast | $-0.36 | $-0.38 | $-0.40 | $-0.41 | $-0.46 | $-0.45 | $-0.48 | $-0.46 | $-0.46 | $-0.44 | $-0.56 | $-0.67 | $-0.70 | $-1.01 | $-1.30 | $-1.80 | $-2.27 | $-2.40 | $-2.43 | $-2.46 | $-2.30 | $-2.01 | $-1.97 | $-2.15 | $-1.93 | $-2.08 | $-2.25 | $-1.76 | $-0.05 | $-0.08 |
| Low Forecast | $-0.36 | $-0.38 | $-0.40 | $-0.41 | $-0.46 | $-0.45 | $-0.48 | $-0.46 | $-0.46 | $-0.48 | $-0.56 | $-0.67 | $-0.70 | $-1.01 | $-1.30 | $-1.80 | $-2.27 | $-2.40 | $-2.43 | $-2.46 | $-2.30 | $-2.01 | $-1.97 | $-2.15 | $-1.93 | $-2.08 | $-2.25 | $-1.76 | $-0.07 | $-0.12 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.80% | - | -0.01% | 0.18% | 0.03% | 0.03% | 0.05% | 0.17% | 0.07% | 0.06% | 0.02% | 0.05% | 0.05% | 0.06% | 0.07% | 2.00% | 1.20% |
According to 1 Wall Street analysts, OncoCyte's projected average Quarter EPS for Jun 23 is $-1.30, with a low estimate of $-1.30 and a high estimate of $-1.30. This represents a -6587.50% decrease compared to OCX previous annual EPS of $0.02 (Mar 23).
OncoCyte Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| DRIO | DarioHealth | $0.95 | $10.75 | 1031.58% | Buy |
| STIM | Neuronetics | $0.73 | $8.00 | 995.89% | Buy |
| PRPH | ProPhase Labs | $2.45 | $14.00 | 471.43% | Hold |
| OCX | OncoCyte | $3.08 | $8.08 | 162.34% | Buy |
| GTH | Genetron | $4.03 | $10.00 | 148.14% | - |
| XGN | Exagen | $2.96 | $6.00 | 102.70% | Buy |
| BDSX | Biodesix | $1.77 | $3.00 | 69.49% | Buy |
| PSNL | Personalis | $5.69 | $7.75 | 36.20% | Hold |
| CSTL | Castle Biosciences | $31.18 | $38.00 | 21.87% | Buy |
| SHC | Sotera Health Company | $16.80 | $16.93 | 0.77% | Buy |
| OLK | Olink AB (publ) | $26.08 | $21.50 | -17.56% | Hold |
OCX Forecast FAQ
Is OncoCyte a good buy?
Yes, according to 4 Wall Street analysts, OncoCyte (OCX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 75.00% of OCX's total ratings.
What is OCX's price target?
OncoCyte (OCX) average price target is $8.08 with a range of $4.25 to $10, implying a 162.34% from its last price of $3.08. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will OncoCyte stock go up soon?
According to Wall Street analysts' prediction for OCX stock, the company can go up by 162.34% (from the last price of $3.08 to the average price target of $8.08), up by 224.68% based on the highest stock price target, and up by 37.99% based on the lowest stock price target.
Can OncoCyte stock reach $5?
OCX's average twelve months analyst stock price target of $8.08 supports the claim that OncoCyte can reach $5 in the near future.
What are OncoCyte's analysts' financial forecasts?
OncoCyte's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.57M (high $1.57M, low $1.57M), average EBITDA is $-944K (high $-944K, low $-944K), average net income is $-23.616M (high $-23.616M, low $-23.616M), average SG&A $18.18M (high $18.18M, low $18.18M), and average EPS is $-1.835 (high $-1.835, low $-1.835). OCX's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $9.25M (high $9.25M, low $9.25M), average EBITDA is $-5.549M (high $-5.549M, low $-5.549M), average net income is $-19.849M (high $-19.849M, low $-19.849M), average SG&A $106.93M (high $106.93M, low $106.93M), and average EPS is $-1.542 (high $-1.542, low $-1.542).
Did the OCX's actual financial results beat the analysts' financial forecasts?
Based on OncoCyte's last annual report (Dec 2022), the company's revenue was $958K, which missed the average analysts forecast of $9.96M by -90.38%. Apple's EBITDA was $-30.399M, beating the average prediction of $-20.757M by 46.45%. The company's net income was $-73.44M, beating the average estimation of $-69.977M by 4.95%. Apple's SG&A was $23.01M, missing the average forecast of $109.24M by -78.93%. Lastly, the company's EPS was $-0.66, missing the average prediction of $-9.552 by -93.09%. In terms of the last quarterly report (Sep 2023), OncoCyte's revenue was $429K, beating the average analysts' forecast of $312.5K by 37.28%. The company's EBITDA was $-6.513M, beating the average prediction of $-188K by 3373.60%. OncoCyte's net income was $-6.687M, missing the average estimation of $-12.978M by -48.47%. The company's SG&A was $3.2M, missing the average forecast of $3.61M by -11.42%. Lastly, the company's EPS was $-0.81, missing the average prediction of $-1.008 by -19.67%